Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +44 1494 818 025 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
+44 1494 818 025

I was really impressed with Zenopa’s assistance in the whole process of finding a job. From beginning to end they did their best for me and were always on hand to answer my many questions.
Sioned, 2014

Biogen Idec publishes positive multiple sclerosis drug trial data

20 September 2012 11:36 in Pharmaceutical Company Product News

Biogen Idec has announced the publication of new clinical data supporting the strong potential of its new multiple sclerosis (MS) treatment BG-12.

Data from the phase III trials Define and Confirm have appeared in the New England Journal of Medicine, showing that the dimethyl fumarate therapy was able to deliver significant and clinically meaningful reductions in MS relapses and brain lesions.

The therapy is intended for patients with relapsing-remitting forms of MS and is currently under review by regulatory authorities in Europe, the US, Australia, Canada and Switzerland.

According to the manufacturer, the latest data shows that BG-12 can deliver tangible benefits for MS patients across the world.

Dr Katherine Dawson, senior medical director at Biogen Idec's neurology research and development unit, said: "We are working closely with regulatory authorities across the globe with the aim of making the review of dimethyl fumarate as quick as possible."

Earlier this month, the company announced the sale of its royalty rights to the systemic lupus erythematosus therapy Benlysta, thus allowing it to accelerate payments that would otherwise have been spread over a longer period.ADNFCR-8000103-ID-801453065-ADNFCR

Other news stories from 20/09/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd